24/7 Market News – (NASDAQ:SNGX) Soligenix Inc. receives FDA clearance for phase 2 clinical trial.

June 28, 2022

Shares are up 11% in pre-market trading. on more than 1100 trades shares are at .62

[mstock id=”73007″ asset=”sngx”]

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis

https://www.prnewswire.com/news-releases/soligenix-receives-fda-ind-clearance-for-phase-2-clinical-trial-of-synthetic-hypericin-in-the-treatment-of-psoriasis-301575751.html

Pages: 1 2

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.